Philips appoints Julia Strandberg as Chief Business Leader of the Connected Care businesses
March 13, 2023
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the appointment of Julia Strandberg as the Chief Business Leader of its Connected Care businesses, effective April 24, 2023. Ms. Strandberg will become a member of Philips’ Executive Committee reporting to Philips CEO Roy Jakobs. As of April 1, 2023, Philips’ Connected Care businesses will comprise the Monitoring, Sleep & Respiratory Care and Enterprise Informatics businesses.
Ms. Strandberg (American, 1974) joins Philips from Pear Therapeutics, where she served as the Chief Commercial Officer leading the commercial team that built, launched and grew their prescription digital therapeutics offering. Prior to this, Ms. Strandberg led a healthcare business consulting firm focused on driving client growth, and before this, she led Medtronic’s global Health Informatics and Monitoring business, and was the global marketing leader for the Patient Monitoring business within Covidien’s Respiratory & Monitoring group, which was acquired by Medtronic. Ms. Strandberg started her career at 3M, where she worked across a number of roles at the company.
“On behalf of Philips’ Executive Committee, I am delighted to announce that Julia Strandberg will join Philips as our new Chief Business Leader of the Connected Care businesses and member of the Executive Committee,” said Roy Jakobs, CEO of Royal Philips. “Julia brings deep, multi-disciplinary expertise, including in informatics and monitoring, to Philips. Passionate about improving the healthcare experience for patients and providers across care settings, Julia understands how to deliver in the global healthcare ecosystem and adds extensive experience in developing and commercializing medical technologies.”
Ms. Strandberg succeeds Dan Leonard, who took on the role of Chief Business Leader Connected Care ad interim when Roy Jakobs became CEO in October, 2022.
Philips’ strong brand and compelling purpose appeal to and attract talent, and the company has therefore continued to strengthen the organization with new health technology talent, including seasoned leaders with deep expertise. Ms. Strandberg ’s appointment to Philips’ Executive Committee builds on the recent appointments of Wim Appelo as Philips’ Chief Operations Officer and Steve C. de Baca as Philips’ Chief Patient Safety & Quality Officer, as well as the promotion of Jeff DiLullo to Philips’ Chief Market Leader of North America.
Additional information on Philips’ Executive Committee can be found here.
For further information, please contact:
Philips Global Press Office
Tel.: +31 615213446
Philips Investor Relations
Tel.: +31 20 59 77055
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
Upcoming Life Sciences Events
- March 2023
- Basel: BIO-Europe Spring® 2023
- Zurich: Swiss Nordic Bio 2023
- April 2023
- Basel: Swiss Biotech Day 2023